Conferences


6th Binaytara Precision Oncology Summit: At The Forefront of Targeted Cancer Therapy conference hero image

6th Binaytara Precision Oncology Summit: At The Forefront of Targeted Cancer Therapy

Accreditation: 10.00 AMA PRA Category 1 Credit™ | 10.00 ABIM MOC II | 10.00 Nursing Contact Hours | 10.00 ACPE Pharmacy

Venue: Hyatt Regency San Francisco Downtown SOMA, 50 3rd Street, San Francisco, CA, United States

Start Date: End Date:
Register for ConferenceCall for Abstract

Official conference page for 6th Binaytara Precision Oncology Summit: At The Forefront of Targeted Cancer Therapy.

About 6th Binaytara Precision Oncology Summit: At The Forefront of Targeted Cancer Therapy

Conference
Conference attendees

Overview

Trusted by Thousands of Attendees
Across Our Events

Binay Shah
32+

Faculty and committee

Our Speakers

Faculty

Conference program and agenda

Our Agenda

Day 1: Friday, September 11th, 2026

All timings are in Pacific Time (PDT, GMT-07:00) time.

09:00 AM - 10:00 AMRegistration, Breakfast, & Exhibits
10:00 AM - 10:30 AMSession 1: Key Note Address

10:00 AM - 10:30 AM

Target Discovery and Validation Dennis Slamon, MD, PhD

10:30 AM - 11:45 AM Session 2: Germline Alterations in Human Cancers

Session Chair: Pamela Munster, MD

10:30 AM - 10:45 AM

Overview of germline vs. somatic mutations in cancer predisposition - Role in therapy selection across tumor types Siddhartha Yadav, MD

10:45 AM - 11:00 AM

Current targeted therapies for germline alterations in Breast Cancer Melinda L. Telli, MD

11:00 AM - 11:15 AM

Future Pipeline Agents Targeting Germline DNA alterations in Cancer Medicine Pamela Munster, MD

11:15 AM - 11:30 AM

An Academic Journey from Gene Discovery to First-in-Class FDA Approval for Familial and Sporadic Kidney Cancer James Brugarolas, MD, MD

11:30 AM - 11:45 AM

Panel Discussion

Moderators:

Pamela Munster, MD

Panelists:

Siddhartha Yadav, MD; Melinda L. Telli, MD; James Brugarolas, MD, MD

11:45 AM - 01:00 PMSession 3: Molecular Diagnostics in Precision Oncology

Session Chair: James M. Ford, MD

11:45 AM - 12:00 PM

NHS-Galleri Trial Elizabeth O' Donnell, MD

12:00 PM - 12:15 PM

Sensitive Detection of MRD in Early-stage Cancer Milana v Dolezal, MD

12:15 PM - 12:30 PM

Controversies in Treatment-emergent Drug Resistance Mutations: Intervention Prior to RECIST Disease Progression Pedram Razavi, MD PhD

12:30 PM - 01:00 PM

Panel Discussion

Moderators:

James M. Ford, MD

Panelists:

Elizabeth O' Donnell, MD; Milana v Dolezal, MD; Pedram Razavi, MD PhD

01:00 PM - 02:00 PMLunch & Exhibits
01:00 PM - 01:45 PMResearch Poster Presentation
02:00 PM - 03:00 PMAntibody-based Therapeutics

Session Chair: Arun Wiita, MD, PhD

02:00 PM - 02:15 PM

Novel ADC Linker/Payload Considerations Mark Daniel Pegram, MD

02:15 PM - 02:30 PM

Therapeutic strategies targeting brain metastases Nancy Lin, MD

02:30 PM - 03:00 PM

Panel Discussion

03:00 PM - 03:20 PMBreak & Exhibits
03:20 PM - 04:20 PMMolecular Tumor Board 1: Interesting and Challenging Cases in Precision Oncology

Session Chair: James M. Ford, MD

04:20 PM - 05:35 PMDrug Resistance in Precision Oncology

Session Chair: Vivek Subbiah, MD

04:20 PM - 04:35 PM

Adaptive Feedback and Bypass Pathways Trever Bivona, MD, PhD

04:35 PM - 04:50 PM

Mechanisms of ADC Resistance Naoto Ueno, MD, PhD, FACP

04:50 PM - 05:05 PM

Tumor Microenvironment Role Judith A. Varner, PhD

05:05 PM - 05:35 PM

Panel Discussion

05:35 PM - 05:35 PMAdjourn Day 1

Day 2: Saturday, September 12th, 2026

07:00 AM - 08:00 AMRegistration, Breakfast & Exhibits

Venue and map

Accreditations and continuing education

Accreditation

Registration and pricing

Exhibitors and sponsorship